US 11,771,695 B2
Cannabinoid receptor modulators
Jayant Thatte, San Diego, CA (US); Anthony C. Blackburn, San Diego, CA (US); Sangdon Han, San Diego, CA (US); Robert M. Jones, San Diego, CA (US); Jae-Kyu Jung, San Diego, CA (US); Antonio Garrido Montalban, San Diego, CA (US); Biman B. Pal, San Diego, CA (US); Jaimie Karyn Rueter, San Diego, CA (US); Sonja Strah-Pleynet, Newton, MA (US); Lars Thoresen, San Diego, CA (US); Yifeng Xiong, San Diego, CA (US); Dawei Yue, San Diego, CA (US); and Xiuwen Zhu, San Diego, CA (US)
Assigned to Arena Pharmaceuticals, Inc., San Diego, CA (US)
Filed by Arena Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Sep. 17, 2021, as Appl. No. 17/478,274.
Application 17/478,274 is a continuation of application No. 16/442,734, filed on Jun. 17, 2019, abandoned.
Application 16/442,734 is a continuation of application No. 15/831,742, filed on Dec. 5, 2017, abandoned.
Application 15/831,742 is a continuation of application No. 15/279,576, filed on Sep. 29, 2016, granted, now 9,867,822, issued on Jan. 16, 2018.
Application 15/279,576 is a continuation of application No. 14/956,586, filed on Dec. 2, 2015, granted, now 9,492,447, issued on Nov. 15, 2016.
Application 14/956,586 is a continuation of application No. 14/001,131, abandoned, previously published as PCT/US2012/026517, filed on Feb. 24, 2012.
Claims priority of provisional application 61/446,729, filed on Feb. 25, 2011.
Prior Publication US 2022/0241274 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/497 (2006.01); C07D 231/54 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 405/14 (2006.01); C07F 9/6558 (2006.01); A61K 31/416 (2006.01); A61K 31/4439 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61K 31/13 (2006.01); A61K 31/485 (2006.01)
CPC A61K 31/497 (2013.01) [A61K 31/13 (2013.01); A61K 31/416 (2013.01); A61K 31/4439 (2013.01); A61K 31/485 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); C07D 231/54 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 405/14 (2013.01); C07F 9/65583 (2013.01)] 11 Claims
 
1. A method for the management of pain in an individual in need thereof, comprising administering to said individual, a composition comprising a compound which is:

OG Complex Work Unit Chemistry
and one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents; and a pharmaceutically acceptable carrier;
wherein the pain is chosen from: bone and joint pain, pain associated with osteoarthritis, hyperalgesia, allodynia, inflammatory pain, inflammatory hyperalgesia, neuropathic pain, neuropathic hyperalgesia, acute nociception, muscle pain, dental pain, migraine and other headache pain, pain that occurs as an adverse effect of therapeutics in an individual, and pain associated with a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and an autoimmune condition.